View Older Stories
-
This medical stock remains undervalued despite its potential, Jefferies says
-
Jefferies says this healthcare stock is one of its top picks
-
McKesson (MCK) PT Raised at TD Cowen After a 'Strong, Steady Performance'
-
McKesson (MCK) PT Raised to $1,065 at Jefferies
-
McKesson (MCK) files mixed shelf
-
McKesson (MCK) Tops Q3 EPS by 18c, Beats on Revenue; Offers FY26 EPS Guidance
-
McKesson completes sale of Norwegian operations to NorgesGruppen
-
McKesson (MCK) PT Raised to $966 at Morgan Stanley
-
McKesson (MCK) PT Lowered to $85 at Bernstein SocGen Group
-
McKesson (MCK) PT Lowered to $80 at BofA Securities
-
McKesson (MCK) PT Lowered to $74 at Jefferies
-
TD Cowen Shares Takeaways From Meetings With McKesson (MCK) Management
-
BofA Comments on GLP-1s and Potential Pressure Ahead
-
These are the best U.S. healthcare tech and distribution stocks to buy: Barclays
-
McKesson (MCK) PT Raised to $965 at Leerink Partners
-
McKesson (MCK) PT Raised to $1,000 at Evercore ISI
-
McKesson (MCK) Tops Q2 EPS by 82c, Misses on Revenue; Offers FY26 EPS Guidance
-
McKesson (MCK) call put ratio 1 calls to 1 put into quarter results
-
Citius Oncology signs distribution deal with McKesson for LYMPHIR launch
-
McKesson (MCK) PT Raised to $864 at TD Cowen
-
McKesson (MCK) PT Raised to $860 at UBS on Growth Outlook From Analyst Day
-
McKesson (MCK) PT Raised to $770 at Mizuho
-
McKesson (MCK) PT Raised to $850 at Leerink Partners
-
McKesson (MCK) call put ratio 1.8 calls to 1 put as share price up 6.8%
-
McKesson raises fiscal 2026 earnings guidance, updates long-term targets
-
McKesson (MCK) PT Lowered to $84 at Jefferies
-
McKesson reorganizes into five segments effective Q2 fiscal 2026
-
Morgan Stanley unveils 16 ‘Vintage Values’ stocks for 2026
-
Morgan Stanley lists top value stocks to own for 2026
-
McKesson (MCK) PT Lowered to $79 at UBS
-
McKesson (MCK) Tops Q1 EPS by 7c; offers guidance
-
McKesson (MCK) PT Raised to $770 at Morgan Stanley, Top Pick
-
Wells Fargo Reiterates Equal Weight Rating on McKesson (MCK)
-
McKesson (MCK) Corporation Completes Acquisition of Core Ventures
-
McKesson (MCK) PT Raised to $800 at Jefferies
-
McKesson (MCK) Tops Q4 EPS by 31c, Misses on Revenue; Offers FY26 EPS Guidance
-
Increasing unusual put option volume: INDA PLNT MAT BCE SN SRPT TAP BTG WGS MCK
-
McKesson (MCK) PT Raised to $690 at Mizuho
-
McKesson (MCK) PT Raised to $745 at Morgan Stanley
-
McKesson (MCK) PT Raised to $685 at Citi
-
McKesson (MCK) Misses Q3 EPS by 24c, lifts guidance
-
McKesson (MCK) to Acquire Controlling Interest in PRISM Vision Holdings, LLC
-
Mizuho Reiterates Neutral Rating on McKesson (MCK)
-
McKesson (MCK) PT Raised to $695 at TD Cowen; 'We View MCK as Best Positioned to Outperform'
-
McKesson (MCK) Completes Divestiture of Canada-Based Rexall and Well.ca Businesses
-
Mizuho Starts McKesson (MCK) at Neutral
-
McKesson (MCK) PT Raised to $715 at Jefferies
-
McKesson (MCK) PT Raised to $550 at Mizuho
-
Baird Upgrades McKesson (MCK) to Outperform
-
McKesson (MCK) Tops Q2 EPS by 15c, Beats on Revenue

